Cafepharma Today

May 16 2025 - Novo CEO to depart as obesity drugmaker’s challenges rise
Novo CEO to depart as obesity drugmaker’s challenges rise
BioMarin expands enzyme expertise with $270M Inozyme buy
Amgen could owe Regeneron more than $400M after defeat in cholesterol drug antitrust suit
Eli Lilly collaborates with Rznomics on hearing loss treatment in $1.3 billion pact
*please scroll down for all the latest news *

Make it like cafepharma, but for different industries. Learn more about CompanyUnderground

Check open job listings in your area
Click here to stay updated on CP happenings

learn about pharmaceutical fraud
learn about the False Claims Act
learn about clinical lab fraud

Current News

submit a press release

Pfizer announces top-line results of two Phase 3 trials of Tofacitinib
Yahoo/Fly on the Wall
Wednesday, October 9, 2013 - 8:47am
tags:
Pfizer, tofacitinib, chronic plaque psoriasis, Janus kinase inhibitor
The Medicines Co. completes two trials for antiplatelet agent
Yahoo/Fly on the Wall
Wednesday, October 9, 2013 - 8:42am
tags:
antiplatelet therapy, Medicines Company, Brilinta, Effient
Knockoff Lust: AbbVie's $9 Billion-A-Year Humira
Seeking Alpha
Wednesday, October 9, 2013 - 8:25am
tags:
AbbVie, Humira, JNJ, Amgen, rheumatoid arthritis
Novartis - Make Money From COPD Opportunity
Seeking Alpha
Tuesday, October 8, 2013 - 5:06pm
tags:
COPD, Novartis, GSK, Theravance, Pfizer, Ultibro Breezhaler
Tonix Developing Treatment Overlap For Fibromyalgia And PTSD
Seeking Alpha
Tuesday, October 8, 2013 - 3:53pm
tags:
Tonix, PTSD, fibromyalgia, Forest Labs, Eli Lilly, Pfizer
Post-restructuring, Pfizer R&D focused on its top blockbuster prospects
Fierce Biotech
Tuesday, October 8, 2013 - 9:43am
tags:
R&D, Pfizer
J&J snaps up an NS5A inhibitor from GlaxoSmithKline for hep C cocktail
Fierce Biotech
Tuesday, October 8, 2013 - 9:41am
tags:
JNJ, NS5A Inhibitors, GSK, hepatitis C, simeprevir, GSK2336805
Teva 'very confident' in timeline for generic Advair
The Fly on the Wall
Tuesday, October 8, 2013 - 9:39am
tags:
Teva, Advair, generics
The U.S. House of Representatives votes to fund the FDA until the federal shutdown ends, or until Dec. 15, whichever comes first
Mass Device
Tuesday, October 8, 2013 - 9:37am
tags:
FDA
2 Companies Offering Hope In the Fight Against Parkinson’s Disease
Wall St. Cheat Sheet
Tuesday, October 8, 2013 - 9:07am
tags:
Parkinson's Disease, Acadia, International Stem Cell Corp, pimavanserin, parthenogenesis
FirstWord Lists: Merck & Co. extends its lead atop the 'pharma job cuts' league table
First Word Pharma
Tuesday, October 8, 2013 - 8:44am
tags:
Merck, layoffs
Alnylam advances Development Candidate for ALN-AS1
Yahoo/Fly on the Wall
Tuesday, October 8, 2013 - 8:43am
tags:
Alnylam, ALN-AS1, hepatic porphyrias
Arena - Tracking Belviq Refills
Seeking Alpha
Tuesday, October 8, 2013 - 8:41am
tags:
Belviq, Eisai, Arena Pharmaceuticals, obesity
Pluristem's Promising GvHD Indication Pits It Against Osiris
Seeking Alpha
Tuesday, October 8, 2013 - 8:41am
tags:
Pluristem, graft vs host disease, Osiris, stem cells
Are These 2 High-Flying Biotech Stocks a Buy?
Motley Fool
Tuesday, October 8, 2013 - 8:39am
tags:
Cell Therapeutics, pacritinib, INSYS Therapeutics, Subsys
Supreme Court Rejects Novartis Bid To Hear Punitive Damages Case
Pharmalot
Tuesday, October 8, 2013 - 8:37am
tags:
Novartis, Supreme Court, FDA
Bayer to bring five mid-stage drugs into Phase III by 2015
Reuters
Tuesday, October 8, 2013 - 8:36am
tags:
Bayer, oncology, cardiology, Women's Health
Glaxo Malaria Shot Protects for 18 Months in Africa Study
Bloomberg
Tuesday, October 8, 2013 - 8:35am
tags:
GSK, vaccines, malaria, RTS, S
The Shutdown: An Update on FDA Activities
FDA Law Blog
Tuesday, October 8, 2013 - 8:34am
tags:
FDA
pSivida: Previewing The Possible Effect On The Stock Of The October 17th PDUFA Date For Iluvien
Seeking Alpha
Tuesday, October 8, 2013 - 8:33am
tags:
pSivida, Iluvien, Alimera, diabetic macular edema

Pages

Latest CP Wire Articles

Hermes Intelligence Launches to Redefine Pharma Data Solutions [sponsored]
The Evolution of Medical Sales: What’s Changing in 2025?
FDA Scraps Key Vaccine Meetings—What It Means for Manufacturers
FDA approves Danziten, the first nilotinib treatment for Ph+ CML with no mealtime restrictions
Daily U.S. Flu Cases Expected to Nearly Double from Last Year by Late November, Predicts Novel Mathematical Forecasting Tool
PharmaBlock Receives 2024 ACS CMO Excellence in Green Chemistry Award, Marking a Second Consecutive Year of Recognition
Leading Clinical Research Network Centricity Research Acquires North Carolina-based Lucas Research
First-of-Its-Kind Alzheimer’s Disease Simulation Paves Way for Personalized Treatment: Penn State, Duke University Study
Centricity Research Appoints New CEO, CFO to Support Next Phase of Growth
Sermo Barometer Examines Influencers’ Impact on Patient Perceptions of Weight Loss Medications & Preventative Care Technologies

Latest Pharmagather Articles

Alzheimer's Update: Infectious Agents and Gamma-Secretase Too
In the Pipeline
Obesity Without Metabolic Dysfunction?
In the Pipeline
New Cell Therapy For Resistant Hodgkins Patients
In the Pipeline
Escape From the Lysosome
In the Pipeline
Heavy Water in Your NMR Experiments, And Elsewhere
In the Pipeline
GIPR: Agonists and Antagonists Do the Same Thing, But How
In the Pipeline
Mutant Proteins Classified
In the Pipeline
The Continuing Crisis, Part XIV: The Trumpist Worldview
In the Pipeline
Whole Lotta Snakin' Going On
In the Pipeline

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.